www.thelancet.com Vol 369 June 23, 2007
MGK, AF, DE, and MJD designed the study. MJD sponsored the FDA
IND. Preparation and characterisation of viral vectors were done by PAL,
RJB, HLF, and DY. Surgical procedures were done by MGK, and
infusions were done by MGK and MJD. Pre-surgical clearance was done
by MGK and KS. All UPDRS ratings, other clinical measurements, and
PET studies, before surgery and at all subsequent timepoints, were
undertaken by AF and DE. AF and DE also had ﬁ nal control over patient
recruitment and entry into the study. HLF measured immunoglobulins
in the serum of patients. Statistical analysis was done by CT. Data
interpretation and writing of the article were primarily done by MGK,
AF, DE, and MJD, with contributions from all authors. MGK and AF,
and DE and MJD, contributed equally to this study.
Conﬂ ict of interest statement
MGK and MJD are founders of and consultants to Neurologix, which
funded this study. They and their families have substantial ownership
interest in the company. HLF and RJB are employees of Neurologix. The
remaining authors, including those responsible for the assessment of
study eligibility, and for the clinical measurements and statistical analyses,
have no involvement in Neurologix and declare no conﬂ ict of interest.
We thank Weidong Xiao and Lei Cao for rAAV infectious titre and rcAAV
assays, respectively, and Dahna Fong and Claudia Leichtlein for technical
assistance. The study was funded by Neurologix. We thank Sumit
Raniga, Scott McPhee, and Meryl Latsko for help in preparing and ﬁ ling
the NIH Recombinant DNA Advisory Committee and FDA
Investigational New Drug applications.
1 Somia N, Verma IM. Gene therapy: trials and tribulations.
Nat Rev Genet 2000; 1: 91–99.
2 Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of
liver in hemophilia by AAV-Factor IX and limitations imposed by
the host immune response. Nat Med 2006; 12: 342–47.
3 Pulkkanen KJ, Yla-Herttuala S. Gene therapy for malignant glioma:
current clinical status. Mol Ther 2005; 12: 585–98.
4 McPhee SW, Janson CG, Li C, et al. Immune responses to AAV in a
phase I study for Canavan disease. J Gene Med 2006; 8: 577–88.
5 Tuszynski MH, Thal L, Pay M, et al. A phase 1 clinical trial of nerve
growth factor gene therapy for Alzheimer disease. Nat Med 2005;
6 Obeso JA, Rodriguez-Oroz MC, Rodriguez M, et al.
Pathophysiologic basis of surgery for Parkinson’s disease. Neurology
2000; 55 (suppl 6): S7–12.
7 Wichmann T, DeLong MR. Pathophysiology of Parkinson’s disease:
the MPTP primate model of the human disorder. Ann N Y Acad Sci
2003; 991: 199–213.
8 Lang AE, Lozano AM. Parkinson’s disease. First of two parts.
N Engl J Med 1998; 339: 1044–53.
9 Nutt JG, Wooten GF. Clinical practice. Diagnosis and initial
management of Parkinson’s disease. N Engl J Med 2005; 353:
10 Erlander MG, Tillakaratne NJ, Feldblum S, Patel N, Tobin AJ. Two
genes encode distinct glutamate decarboxylases. Neuron 1991; 7:
11 Hamani C, Saint-Cyr JA, Fraser J, Kaplitt M, Lozano AM. The
subthalamic nucleus in the context of movement disorders. Brain
2004; 127: 4–20.
12 Emborg ME, Carbon M, Holden JE, et al. Subthalamic glutamic
acid decarboxylase gene therapy: changes in motor function and
cortical metabolism. J Cereb Blood Flow Metab 2007; 27: 501–09.
13 Kaplitt MG, Leone P, Samulski RJ, et al. Long-term gene expression
and phenotypic correction using adeno-associated virus vectors in
the mammalian brain. Nat Genet 1994; 8: 148–54.
14 Lee B, Lee H, Nam YR, Oh JH, Cho YH, Chang JW. Enhanced
expression of glutamate decarboxylase 65 improves symptoms of rat
parkinsonian models. Gene Ther 2005; 12:
15 Luo J, Kaplitt MG, Fitzsimons HL, et al. Subthalamic GAD gene
therapy in a Parkinson’s disease rat model. Science 2002; 298: 425–29.
16 Hoehn MM. The natural history of Parkinson’s disease in the
pre-levodopa and post-levodopa eras. Neurol Clin 1992; 10: 331–39.
17 Metman LV, Myre B, Verwey N, et al. Test-retest reliability of
UPDRS-III, dyskinesia scales, and timed motor tests in patients
with advanced Parkinson’s disease: an argument against multiple
baseline assessments. Mov Disord 2004; 19: 1079–84.
18 Schwab R, England A. Projection technique for evaluating surgery
in Parkinson’s disease. Third symposium on Parkinson’s disease
1969, Edinburgh: 152–157.
19 Asanuma K, Tang C, Ma Y, et al. Network modulation in the
treatment of Parkinson’s disease. Brain 2006; 129: 2667–78.
20 Hobson DE, Lang AE, Martin WR, Razmy A, Rivest J, Fleming J.
Excessive daytime sleepiness and sudden-onset sleep in Parkinson
disease: a survey by the Canadian Movement Disorders Group.
JAMA 2002; 287: 455–63.
21 Chirmule N, Propert K, Magosin S, Qian Y, Qian R, Wilson J.
Immune responses to adenovirus and adeno-associated virus in
humans. Gene Ther 1999; 6: 1574–83.
22 Palombo E, Porrino LJ, Bankiewicz KS, Crane AM, Sokoloﬀ L,
Kopin IJ. Local cerebral glucose utilization in monkeys with
hemiparkinsonism induced by intracarotid infusion of the
neurotoxin MPTP. J Neurosci 1990; 10: 860–69.
23 Herzog RW, Hagstrom JN, Kung SH, et al. Stable gene transfer and
expression of human blood coagulation factor IX after
intramuscular injection of recombinant adeno-associated virus.
Proc Natl Acad Sci USA 1997; 94: 5804–09.
24 Eidelberg D, Moeller JR, Kazumata K, et al. Metabolic correlates of
pallidal neuronal activity in Parkinson’s disease. Brain 1997; 120:
25 Eidelberg D, Moeller JR, Ishikawa T, et al. Regional metabolic
correlates of surgical outcome following unilateral pallidotomy for
Parkinson’s disease. Ann Neurol 1996; 39: 450–59.
26 Su PC, Ma Y, Fukuda M, et al. Metabolic changes following
subthalamotomy for advanced Parkinson’s disease. Ann Neurol
2001; 50: 514–20.
27 Fukuda M, Mentis MJ, Ma Y, et al. Networks mediating the clinical
eﬀ ects of pallidal brain stimulation for Parkinson’s disease: a PET
study of resting-state glucose metabolism. Brain 2001; 124: 1601–09.
28 Oh MY, Abosch A, Kim SH, Lang AE, Lozano AM. Long-term
hardware-related complications of deep brain stimulation.
Neurosurgery 2002; 50: 1268–74.
29 Kleiner-Fisman G, Herzog J, Fisman DN, et al. Subthalamic
nucleus deep brain stimulation: summary and meta-analysis of
outcomes. Mov Disord 2006; 21 (suppl 14): S290–304.
30 Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial
of deep-brain stimulation for Parkinson’s disease. N Engl J Med
2006; 355: 896–908.
31 Simuni T, Jaggi JL, Mulholland H, et al. Bilateral stimulation of the
subthalamic nucleus in patients with Parkinson disease: a study of
eﬃ cacy and safety.
J Neurosurg 2002; 96: 666–72.